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I. Abstract
Previous research using the chicken model has provided evidence that a flaxseedsupplemented diet decreases both the severity and the incidence of ovarian cancer. Flaxseed is a
source of omega-3 (OM3) polyunsaturated fatty acids (PUFA), particularly α-linolenic acid
(ALA). ALA is converted into longer chain OM3s, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), which inhibit prostaglandins, thereby inhibiting oxidative stress,
inflammation, angiogenesis, and proliferation. The dietary fiber component of flaxseed can be
fermented in the gut to produce short chain fatty acids (SCFA). Butyric acid, a commonly studied
SCFA, has been shown be an important metabolic regulator by acting as a histone deacetylase
(HDAC) inhibitor, a transcriptional modulator, as well as an anti-inflammatory molecule. In order
to determine whether or not PUFA and butyric acid are upregulated by flaxseed supplementation
in the chicken ovaries, the concentrations of each were quantified using gas chromatographic
analysis. The amount of fatty acids in each sample were normalized to total protein content. Hens
on a flaxseed-supplemented diet displayed an increase in the ratio of OM3:OM6 PUFA when
compared to the control diet. Likewise, the concentrations of butyric acid were also increased in
ovaries of hens fed a flaxseed-supplemented diet in comparison to hens that were fed a control
diet. Moreover, butyric acid was significantly decreased in both the ovaries and ceca by ovarian
cancer. These observations give us insight into the possible role of flaxseed in modulating
metabolic activity through an upregulation of SCFA and OM3 PUFA in the ovaries.
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II. Introduction
With nearly 22,000 new cases each year, and 14,000 of those cases leading to death,
epithelial ovarian cancer (EOC) is the most lethal among all other gynecologic malignancies
(“Ovarian Cancer Statistics,” 2019). Ovarian cancer usually reaches stage 3 or 4 by the time it is
diagnosed due to insufficient screening mechanisms and lack of symptoms early in the disease.
For this reason, ovarian cancer has been termed the ‘silent killer,’ and is treated, perhaps most
effectively, through prevention. Advancement in the treatment and prevention of ovarian cancer
has been hindered in the past due to the lack of a functional animal model, but has recently begun
to move forward with the introduction of the chicken model. EOC develops spontaneously in the
White Leghorn Laying Hen and closely resembles the human form of the disease. Studies
performed using the chicken model provide the opportunities to conduct large scale dietary
intervention studies in a timely manner due to the fact that 2-year-old White Leghorn Hens ovulate
300-400 times, nearly the same as a perimenopausal woman, and similarly to humans, the risk of
developing the disease and the severity of the disease for the laying hens increases with age.
In previous study conducted in Dr. Hales’ lab, hens fed a 10% flaxseed-supplemented diet
for four years displayed a significant decrease in incidence and severity of ovarian cancer (Eilati,
Bahr et al. 2013), pointing at the possibility of flaxseed acting as a regulator of metabolic activity
and gene expression. Flaxseed is a dietary fiber made up of two major components: omega-3
(OM3) polyunsaturated fatty acids (PUFA) and phytoestrogen lignin (SDG). OM3 PUFA provide
anti-oxidant, anti-inflammatory, anti-angiogenic, and apoptotic effects, thereby preventing cancer
development by inhibiting the actions of prostaglandins. Similarly, SDG is converted into
enterodiol (ED) and enterolactone (EL), which prevent cancer development by blocking
proliferation and mutagenesis via estrogen inhibition. This study was designed specifically to
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explore the role of the fatty acid component of flaxseed by measuring OM3 PUFA levels in
comparison to omega-6 (OM6) PUFA, as well as exploring the effects of flaxseed-supplementation
on prostaglandin synthesis. The dietary fiber component of flaxseed was also investigated by
measuring short chain fatty acid (SCFA) levels in the ovaries to demonstrate possible mechanisms
of flaxseed acting as a metabolic regulator in ovarian cancer.
OM3 PUFA are considered essential fatty acids because they cannot be produced in the
body, and therefore must be consumed by the diet. OM3 PUFA include stearadonic acid (SDA)
(C18:4), alpha-lenolenic acid (ALA) (C18:3), and eicosapentanoic acid (EPA) (C20:5) and
docosahexanoic acid (DHA) (C22:6), which are two byproducts of ALA. ALA serves a variety of
purposes throughout the body, including reducing inflammation, promoting blood vessel health
via incorporation into cell membranes, and being converted into the longer chain OM3 PUFAEPA and DHA (Licastro, Candore et al. 2005). The ability for ALA to be converted into EPA and
DHA is dependent upon diet. By reducing inflammation, ALA helps prevent and manage type 2
diabetes, heart disease, kidney disease, and many other chronic diseases, including some cancers,
and by promoting blood vessel function, it also reduces the risk of heart attacks and stroke
(Licastro, Candore et al. 2005). In addition, ALA produces energy for muscles by undergoing βoxidation, can be used to make ketone bodies, and is stored in adipose tissue to serve as a reserve
supply of energy.
ALA itself, however, does not have as many well described health benefits as EPA and
DHA, but once consumed by the diet, ALA can be converted into these longer chain PUFA through
a series of steps occurring in the endoplasmic reticulum, which involve alternating desaturations
and elongations. Desaturase enzymes add double bonds to the fatty acids by removing hydrogen,
while elongase enzymes add two additional carbons. ALA metabolism begins with desaturation
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via delta-6-desaturase enzyme, forming SDA. This step is rate limiting because it is dependent on
nutrition, hormones, and metabolism. The process of desaturation is very slow in comparison to
the rapid process of elongation, so SDA is usually found in very low concentrations because once
it is formed, it is quickly elongated to 20:4n3 (Licastro, Candore et al. 2005). 20:4n3 is then
desaturated by delta-6-desaturase enzyme to produce EPA, which is also quickly elongated,
forming docasapentaenoic acid (DPA) (C22:5). DPA is found in very trace amounts, as it is also
quickly elongated to form 24:5n3. 24:5n3 then gets desaturated again, forming 24:6n3, which is
finally β-oxidized to produce the end product of ALA metabolism: DHA (Licastro, Candore et al.
2005). Because this is the final step, DHA is often present in larger concentrations than the other
OM3 PUFA. Following the metabolism of ALA, EPA and DHA can be incorporated throughout
the body and further contribute to the viscosity of cell membranes, alterations in immune and
tumor cell function, anti-inflammatory actions, and treatment or prevention of various diseases,
such as cancer and cardiovascular disease (Swanson, Block et al. 2012). However, ALA
metabolism does not always make it all the way to DHA. Some factors that can affect the
conversion of ALA to EPA, DPA, and DHA include gender, smoking, and diet (Licastro, Candore
et al. 2005). Cigarette smoke has been shown to reduce the conversion of ALA to EPA and DHA.
Men also show a reduced metabolism of ALA compared to women, who are likely more sensitive
to diet than women due to their unique hormonal profile. Women’s increased ability to convert
ALA to DHA is very important during pregnancy and breast feeding (Licastro, Candore et al.
2005). Lastly, a diet that is rich in OM6 PUFA significantly decreases the conversion of ALA, in
addition to diets that are high in saturated fats, oleic acid, trans fatty acids, and cholesterol, which
disrupt the actions of desaturase and elongase enzymes (Licastro, Candore et al. 2005). These
factors suggest that ALA conversion is very dependent on one’s individual metabolic capacity. If
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dietary flaxseed increases the levels of OM3 PUFA compared to OM6 PUFA, and therefore
increases the levels of DHA converted from ALA, this could demonstrate one mechanism in which
flaxseed works to improve overall metabolism could be revealed.
OM6 PUFA, like OM3, are essential fatty acids and must be consumed from the diet.
However, because these two groups of fatty acids cannot interconvert between one another, there
is competition between the metabolism of the two (Licastro, Candore et al. 2005). Excess of one
can affect the metabolism of the other because they use similar mechanisms, involving the same
desaturase and elongase enzymes. OM6 PUFA are typically consumed much more abundantly
than OM3, and primarily include linoleic acid (LA) (C18:2) and arachidonic acid (AA) (C20:4).
LA consumed from the diet is desaturated to produce gamma-linolenic acid (GLA) (C18:3). GLA
is elongated, forming dihomo-gamma-linolenic acid (DGLA) (C20:3). This fatty acid is
desaturated to make AA, which is elongated and desaturated to eventually form DPA following βoxidation. AA is known to be the primary source for prostaglandins. Prostaglandins consist of a
20-carbon, unsaturated fatty acid chain and are synthesized via the cyclooxygenase (COX1 and
COX2) pathway (Chen, Wang et al. 2019). Prostaglandins can be harmful by causing
inflammation, oxidative stress, angiogenesis, and proliferation. The action of prostaglandins can
be inhibited by increasing the levels of OM3 PUFA, which will use the enzymes needed by OM6
PUFA to produce AA. By decreasing the
amount of AA converted from LA, the levels
of prostaglandins will also be reduced. By
showing a negative correlation between
dietary flaxseed and AA / prostaglandin
synthesis, another mechanism in which
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flaxseed has the ability to improve metabolic activity, specifically by regulating inflammation and
oxidative stress, could be observed.
The relationship between diet and gut microbiota strongly influences metabolic health by
the bacterial synthesis of various metabolites, such as SCFA, which are fermented by bacteria in
the gut from dietary fibers. Different dietary fibers are fermented differently based on fiber
structure, which could favor or disfavor growth, and type of bacteria, which have varying
metabolites that alter the gut microenvironment in different ways (Bishehsari, Engen et al. 2018).
Pleiotropic effects, including immune system modulation, anti-inflammatory effects, and
alterations in pathogen susceptibility, have been associated with an upregulation of SCFA, such as
acetate, propionate, and butyrate (Shubham, Chakravarty et al. 2019). For this reason, SCFA are
being studied as a possible preventative mechanism for various diseases, and in this case, ovarian
cancer.
One SCFA in particular, butyric acid (C4:0), has been previously reported to have an
exceptionally beneficial role in immunity. The SCFA facilitates an immune response by altering
various catabolic processes in human cells and by modulating gene expression by acting as an
HDAC inhibitor (Shubham, Chakravarty et al. 2019). HDAC inhibitors favor histone acetylation,
resulting in an open and transcriptionally active form of chromatin. Through its HDACi activity,
butyric acid has been shown to improve insulin signaling by upregulating the expression of IRS1,
protect against oxidative stress linked to the over-expression of FOXO3a and PGC-1α, (Chriett,
Dabek et al. 2019). In addition, butyric acid upregulates the activity of various mitochondrial
genes, including the mitochondrial sirtuins (SIRT3, 4, and 5) responsible for regulation of
mitochondrial activity, SOD2, and CPT1b, and also contributes to the expression of catalase,
which functions in cell defense, especially against oxidative stress (Chriett, Dabek et al. 2019). All
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of these genes are upregulated by butyric acid and function to improve cellular immunity, protect
against oxidative stress, and regulate mitochondrial activity, enhancing overall metabolic activity
and protecting the body from various diseases. Thus, identifying whether SCFA, in particular
butyric acid, are upregulated by a flaxseed supplemented diet could provide insight into one
mechanism for preventing or reducing the severity of ovarian cancer.
The objective for the current study was to better understand the role of dietary flaxseed in
regulating metabolic activity and gene expression by exploring the levels of PUFA and SCFA in
the ovaries collected from White Leghorn laying hens. The 2-year old hens were placed on one of
six diets, four of which were flax based diets, and are outlined below in Table 1. The other two
diets included fish oil and corn oil to further investigate the effect of diet on fatty acid production.
After 11 months, a necropsy was performed to collect various samples from the birds, including
the ovaries. The ovarian tissues were then analyzed to determine the concentrations of PUFA and
SCFA in each sample. A simple lipid extraction was performed first to separate the lipids from the
other components of the sample. Fatty acid methyl ester (FAME) preparation was then performed
to prepare the samples for gas chromatographic analysis. By performing gas chromatography, the
concentrations of fatty acids in each sample was determined and the data was normalized to protein
content. An enzyme linked immune-sorbent assay (ELISA) was performed on the same ovarian
samples to measure the levels of prostaglandin in each sample. This data was normalized to the
protein content. In order to better understand the synthesis and distribution of SCFA in the body,
the ceca were also analyzed using the same method as the ovaries previously discussed. These
concentrations were then compared to the concentrations of the SCFA in the ovaries. The analysis
revealed that hens that were fed a flaxseed-supplemented diet had higher levels of OM3 PUFA
compared to OM6 PUFA in both the ovaries and the ceca. The concentrations of SCFA were also
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slightly increased in the ovaries and ceca of flax-fed hens compared to the control group. More
significantly than the effect of diet, this analysis showed that ovarian cancer results in a significant
increase of SCFA concentrations in the ovaries and the ceca. These observations give us insight
into the possible role of flaxseed in modulating metabolic activity through an upregulation of
SCFA and PUFA in the ovaries.
Table 1: Content of flaxseed diets

Control

15%
(WF)

Whole

Flax

5%
Flax
(FXO)

Oil

15% Defatted
(DFM)

SDG + ALA

ALA

SDG

Omega
3/6

Omega 3 Rich

Omega 3 Rich

Low Omega 3

No SDG

High SDG

No SDG

High SDG

Flax

Meal

III. Material and Methods
Lipid Extraction
Ovarian tissues were collected and 200 mg were aliquoted into glass test tubes. Samples were
homogenized with 1mL of homogenate buffer (20x Protease Inhibitor and 10mM Tris Buffer)
using Tissue Tearor Homogenizer (Biospec Products, Inc. USA) on dry ice. 200 µl of the samples
were transferred to new test tubes, and the rest was stored at -20°C until further use. To the 200
µl, 30 µg/mL heptadecanoic acid (C17:0) was added as an internal standard. These samples were
then extracted twice using chloroform and water, and were centrifuged at 3400 rpm, for 10 min.,
at 4°C, between each extraction. The organic layer was removed and stored at -20°C until further
use. This procedure was also used to extract lipids from the ceca, but 2 mL of homogenate was
used, rather than 1 due to increased thickness of these samples.
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Fatty Acid Methyl Ester (FAME) Preparation
Extracted samples were dried under ultra-pure nitrogen (UPN), and acetyl chloride and methanol
was used to convert fatty acids to methyl esters. The oxygen was then flushed out of the samples
using UPN, and the samples were incubated in a dry over for 1 hr. Dried samples were then taken
out to cool, and fatty acids were extracted using hexane and water. The samples were centrifuged
at 3400 rpm, for 10 min, at 4°C. The hexane layer was removed and dried once again under UPN.
125 µl of hexane was then used to re-suspend the dried samples, and the resuspension was
transferred to gas chromatography vials. The vials were capped and stored at -20°C until further
use. The same procedure was used to prepare the ceca for gas chromatographic analysis.
Gas Chromatography
Quantification of FAME was performed using gas chromatography with flame ionization detection
(GC-FID). GC was performed on a Shimadzu GC-2010 Gas Chromatograph equipped with a
Supelco Omegawax 250 capillary column (30 m, 0.25 mm ID, 0.25 µm film thickness). Samples
were injected into a split injector held at 250°C and with helium carrier gas running at a column
flow of 1.25 mL/min with a 100:1 split. Analytes were detected using a flame ionization detector
held at 260°C. All data were acquired and analyzed Shimadzu Chromatography Data System. All
automatic peak assignments and integrations were manually verified.
Protein Analysis
The remainder of the homogenized samples saved during the lipid extraction phase of the
experiment was thawed and used in a protein assay to normalize the data collected from the GC.
First, a standard curve was established using known amounts of protein (BSA [2mg/mL]), diluted
with buffer SDS buffer (0.1% in 1x PBS) in the first two columns of a 96-well plate, using the
amounts shown below in Table 2.
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Table 2: BSA Protein Assay standards performed in replicates. Ratios denote protein (BSA) to buffer (0.1% SDS in 1x PBS)

protein:buffer
(µL)
A
B
C
D
E
F
G
H

Column 1
0:10
1:9
2:8
3:7
4:6
6:4
8:2
10:0

Column 2
(replicate)
0:10
1:9
2:8
3:7
4:6
6:4
8:2
10:0

After the protein and buffer was pipetted to create the standard curve, 2 µl of each unknown ovary
samples were added in triplicates in the subsequent wells with 8 µl of 0.1% SDS buffer in 1x PBS.
Enough of a 50:1 dilution of BCA protein assay reagents A and B (Thermo Fischer Scientific,
USA) was then made to add 200 µl of the mixture to each well, including both the standards and
unknown samples. After the AB reagent mixture has been added to each of the wells, the plate is
incubated in the Synergy plate reader with slow shaking at 37°C for 30 min. Following the
incubation, the plate was read at 562 nm, and absorbance values are used to calculate the
concentration of protein in each sample, which is in turn used to determine the concentration of
fatty acid/mg of protein. The R2 value determined by the accuracy of the standard curve should be
greater than 0.99 to yield the most accurate results. For the ceca, the samples were sonicated prior
to increase liquefaction.
Enzyme Linked Immuno-Sorbent Assay (ELISA)
The same ovaries previously used were aliquoted again with 200 mg in glass test tubes. Samples
were homogenized with 0.5 mL of homogenate buffer (20x Protease Inhibitor and 10mM Tris
Buffer) using Tissue Tearor Homogenizer (Biospec Products, Inc. USA) on dry ice. These samples
were then centrifuged at 3400 rpm, for 10 min., at 4°C, and the supernatant was collected. The
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samples were then set aside for use in the ELISA kit (Cayman Chemical, USA) and the instructions
provided in the kit were followed. First the ELISA and wash buffers were prepared. One vial of
10x ELISA buffer was diluted with 90 mL of UltraPure (UP) water. 2.5 mL of the 400x wash
buffer was diluted to 1 mL with UP water and 0.5 mL of Polysorbate 20 was added. The standards
were then prepared by adding 100µL of the ELISA buffer to the provided ELISA standard. Eight
glass test tubes were then labelled and serial dilutions were performed as follows:

Acetylcholineesterase (AChE) Tracer and Antibody were then prepared by adding 6 mL of ELISA
buffer to each of the 100 dtn vials. The 96-well plate was provided pre-coated with antibody. A
sample of the plate format is shown below:

First, 100 µL of ELISA buffer was added to the NSB wells, and 50 µL of ELISA buffer was added
to the B0 wells. 50 µL of the standards were then added in their coordinating wells beginning with
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S8 and working up to S1. 50 µL of the samples that were previously prepared were then added to
the remaining wells in duplicate. 50 µL of AChE Tracer was then added to all the wells except the
TA and the Blk wells and 50 µL of AChE Antibody was added to each well except the TA, NSB,
and Blk wells. The plate was then covered, and incubated for 18 hours at 4°C. After 18 hours the
wells were emptied and washed 10 times with wash buffer. The 100 dtn Ellman’s reagent was
reconstituted in 20 mL of UP water right before use. 200 µL of this reagent was added to each
well. 5 µL of AChE Tracer was added to the TA well, and the plate was incubated in the Synergy
plate reader with slow shaking at 37°C for 60 minutes. The plate was read at 420 nm, and the
concentrations of prostaglandin E2 (PGE2) were then calculated. A protein assay was again
performed to normalize the data.
Statistical Analysis
Comparison of values between groups was performed by two-way ANOVA, using TukeyKramer’s Post Hoc, p < 0.5 to identify significant values.
IV. Results
Figure 1: Concentrations
protein in ovarian tissues

PROTEIN

μg/μL protein

20
15
10
5
0
CONT

DFM

WF
N

FXO
C

FSH

CRN

of

A protein assay was used to
determine the amount of protein in
each sample. This was then used to
normalize the gas chromatography
data to determine the amount of
fatty acid in each microgram of
protein. The protein assay was
performed in triplicates. R2 = 0.996.
Error bars represent SEM.
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Figure 2: Concentrations of
protein in ceca compared to
ovarian tissues

μg/μL protein

PROTEIN ANALYSIS
2
1.9
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1
N

C

N

C

CONT- OVARY CONT- CECA

N

C

WF- OVARY

N

C

WF- CECA

A protein assay was used to
determine the amount of protein in
each ceca sample. This was then used
to normalize the gas chromatography
data to determine the amount of fatty
acid in each microgram of protein.
The protein content in the ceca
samples were then compared to the
protein content in the ovariean
samples. The data was normalized to
the amount of protein in the ovaries
of healthy, control-fed hens. The
protein assay was performed in
triplicates. R2 = 0.998. Error bars
represent SEM.
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C18:1n9

LA

C18:0
C17:0
Internal
Standard

AA
ALA
EPA

SDA

Figure 3: Whole Flax v. Control
PUFA in cancerous ovarian
tissues

OM3 PUFA (mg/mL) / μg protein

OM3 PUFA
12
10

Gas chromatographic analysis was
performed to determine the
concentrations of PUFA in ovarian
tissues collected from hens fed 6
various diets. C4-C24 FAME mix
was used to identify the fatty acids
(shown in the first chromatograph).
The next chromatograph compares
whole flax (black) with control
(red). C17:0 was used as an internal
standard. The data was normalizaed
using a protein assay, and the effects
of the diet and disease on the ratio of
OM3 to OM6 PUFA in the ovaries
was examined. Error bars represent
SEM. Tukey-Kramer’s Post Hoc,
p<0.05.
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Figure 4: Effect of diet and disease
on the conversion of ALA to DHA
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EPA (mg/mL) / μg protein
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3
2
1

b
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ALA has various fates once it is
introduced to the body. One of these
involves being converted into longer
chain fatty acids, such as EPA and
DHA, by desaturase and elongase
enzymes. A.) Compares the levels of
ALA across all 6 diets in normal and
diseased birds B.) Compares the
levels of EPA alone. C.) Compares
the levels of DHA alone. D.) Displays
a chromatograph zoomed in on the
peak representing DHA to observe
how much DHA has been produced
in WF-fed, healthy birds (red), WFfed, cancerous birds (black), controlfed, healthy birds (blue), and controlfed, cancerous birds (green). The
error bars indicate SEM. TukeyKramer’s Post Hoc, p < 0.05.
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PGE2
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Figure 5: Effect of diet and
cancer on levels of prostaglandin
E2 and arachidonic acid in the
ovaries

ARACHADONIC ACID

AA (mg/mL) / μL protein

10
8
6
4
2
0
N
-2

C
CONT

N

C
DFM

N

C
WF

N

C
FXO

ELISA was performed on ovaries
to also measure the levels of
PGE2. R2 = 0.99. Arachadonic
acid
concentrations
were
determined
using
gas
chromatography.
Data
was
quantified, and compared between
the various diets and between
healthy and diseased hens. Both of
these
concentrations
were
normalized to protein content.
Error bars represent SEM.
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OM3:OM6 IN CECA
0.7

OM3:OM6 PUFA
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Figure 6: Ratio of OM3 to OM6 PUFA in hen ceca
PUFA concentrations were determined by gas chromatography. The levels of a OM3 and OM6 PUFA
were quantified and the effects of diet and disease were then observed. Error bars represent SEM.
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BUTYRIC ACID
b

C4:0 (mg/mL) / μg protein

3
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1
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Figure 7: Diet and carcinogenic effects on butyric acid (C4:0) composition in ovarian tissues
SCFA concentrations were determined by gas chromatography. The levels of a common SCFA, butyric
acid (C4:0), were quantified and compared between the six different diets and between healthy and
diseased hens. Error bars represent SEM. Tukey-Kramer’s Post Hoc, p < 0.05.
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Butyric Acid in Ceca
2

C4:0 (mg/mL) / μg protein
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-1

Figure 8: Effect of diet and cancer on C4:0 production in the ceca compared to levels in the ovaries
Butyric acid (C4:0) concentrations in chicken ceca were determined using gas chromatography. The
levels were quantified and first compared between whole flax and control fed hens, and then between
healthy birds and birds with advanced stage ovarian cancer. The data was normalized to protein content.
The concentrations of C4:0 in the ceca were then compared to the data collected from the ovarian
samples. Error bars represent SEM.
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V. Discussion
The six diets explored in this study were designed to test the hypothesis that OM3 PUFA
and SCFA are upregulated in the ovaries as a result of a flaxseed-supplemented diet, and that this
upregulation may be one mechanism in which flaxseed can work to regulate metabolic activity.
Figure 1 indicates that protein concentrations in the ovaries are not affected by neither diet nor
disease. Figure 2 shows that diet and disease also have no effect on the protein content in the ceca.
Although no effect of diet or disease was observed on either sample, the ceca samples had a much
greater protein content compared to the ovarian samples.
In Figure 3 it is shown that flax-supplemented diets slightly increase the mean levels of
OM3:OM6 PUFA compared to control fed birds in both healthy and diseased states, although the
quantities are not significantly different. This data also indicates that in control fed hens (hens that
were not fed flaxseed as a source of OM3 PUFA), the disease may affect the ability to produce
DHA shown by significantly reduced levels in the birds with ovarian cancer. Figure 4 explored
the efficiency of the conversion of ALA to the longer chain PUFA- EPA and DHA. The data show
that birds with ovarian cancer that are fed a whole flax-supplemented diet more readily convert
ALA to DHA than healthy birds and diseased birds fed a control diet. Levels of ALA vary across
the diets but are lowest in the control and corn oil-fed hens, and levels of EPA remain mostly
consistent. Next, the levels of PGE2 were examined in relation to the levels of AA. Figure 5
indicates that no correlation was observed between these values, however, the levels of PGE2 were
consistent with the trends observed in the ratios of OM3:OM6, indicating that when OM3 PUFA
are increased, less PGE2 is able to be synthesized. It was also noted that AA was significantly
reduced in whole-flax fed hens. The ratios of OM3:OM6 PUFA in the ceca were also determined,
and in Figure 6, it was observed that a whole-flax diet significantly increased the levels of OM3,
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in particular DHA. It was also shown in this data that the levels of DHA in the ceca, which average
between 50 and 70 mg/mL per μg protein, are significantly higher compared to the levels in the
ovaries, which are only between 5 and 10 mg/mL per μg protein. In addition, this data confirmed
that disease state does in fact have an effect on DHA production because in the ovaries of control
fed hens, birds with ovarian cancer had significantly less DHA than healthy birds (shown in Figure
1), but the DHA levels in the ceca had not been affected.
Butyric acid was increased in the oil based diets and flax-supplemented diets, although the
values were not significantly different. Disease state showed to have a greater effect, as observed
in Figure 7, butyric acid was significantly higher in healthy birds than ones with ovarian cancer,
regardless of which diet the hen was fed. This observation signifies a possible impairment in
enteric SCFA production and/or intra-ovarian tissue metabolism. To further explore whether this
was an impairment in SCFA production or function, the levels of butyric acid were measured
where they are produced, in the colon. In Figure 8, it is shown that the levels of butyric acid
observed in the ovaries are consistent with the production in the ceca, showing a slight increase in
the birds fed a whole-flax diet compared to control, and a significant decrease in birds with
advanced stage ovarian cancer compared to healthy birds. However, the levels of butyric acid were
higher in the ovaries than in the ceca, indicating that they likely do not stay in the ceca long before
moving to the liver to be stored and/or to the target organ.
VI. Conclusion
Previously, our lab has shown that a flaxseed-supplemented diet reduces both the incidence
and severity of ovarian cancer. This study aimed to investigate the possible mechanisms in which
flaxseed, when consumed, is able to regulate metabolic activity and gene expression in ovarian
cancer by first, exploring the role of the OM3 component of flaxseed. Because OM3 and OM6
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PUFA cannot be produced by the body, production of these fatty acids is solely dependent on
dietary intake. Gas chromatographic analysis revealed that ratios of OM3:OM6 PUFA are slightly
elevated in the ovaries of birds fed a flaxseed-supplemented diet when compared to the control
group. This data was consistent with the concentrations of AA measured in the ovaries, which
were significantly reduced in flax-fed hens. This is significant because OM3 and OM6 PUFA
compete to use the same elongase and desaturase enzymes. At higher levels of OM3, more DHA
can be produced from ALA, rather than AA from LA, which would lead to increased prostaglandin
synthesis. PGE2 levels were measured using ELISA, and were found to be slightly reduced in hens
that were fed a whole flax or flax oil diets compared to the control group, which is consistent with
the trends observed in the ratios of OM3:OM6, indicating that when OM3 PUFA are increased,
less PGE2 is able to be synthesized. This data is also consistent with the levels of AA measured in
the ovarian samples. These observations further indicate that by increasing levels of OM3 in the
ovaries, a flaxseed-supplemented diet inhibits or significantly reduces the enzymatic activity
available to convert LA into AA, which is required to produce PGE2. By decreasing the levels or
PGE2, the negative side effects of inflammation and oxidative stress are also prevented.
In addition to a reduced overall ratio of OM3:OM6, the birds in the control group that were
not fed a flaxseed-supplemented diet had slightly lower amounts of DHA in their ovaries compared
to the flax-fed birds, and significantly lower amounts of DHA if the birds had ovarian cancer.
However, the same effects were not observed in the ceca, indicating that the cancer likely had a
direct effect on the ability for these hens to convert ALA to DHA at the ovarian tissue level. The
levels of DHA in the flax-fed hens did not seem to be affected by the disease in the ovaries or the
ceca, which suggests that hens that were fed a flaxseed-supplemented diet with ovarian cancer are
more likely to benefit from the anti-cancer effects of DHA, which has greater anti-inflammatory
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and antioxidant effects than ALA alone. Increases in DHA might suggest that flaxseed increases
DHA by increasing Δ6-desaturase activity. The consistent levels of EPA that were observed are
likely due to the fact that desaturase enzymes work very slowly to produce EPA from ALA, but
once formed, EPA is very quickly elongated and converted to DHA by Δ6-desaturase enzymes,
which contributes to why levels of DHA are consistently higher than ALA or EPA.
This study also investigated the role of flaxseed as a dietary fiber, which can be fermented
in the gut to produce SCFA, specifically butyric acid. The flaxseed-supplemented diet exhibited a
slight increase in butyric acid, which has been found to act as an HDAC inhibitor, acting on various
genes responsible for improving cellular immunity, protecting against oxidative stress, regulating
mitochondrial activity, and protecting the body from various diseases. The decreased level of
SCFA observed in ovarian tumors as compared to healthy ovaries indicates impaired enteric
production of SCFA (from dietary fibers) and/or enhanced oxidation of SCFA in ovarian tumors.
This would reduce the effect of SCFA as HDAC inhibitors, transcriptional modulators, and antiinflammatory molecules, in tumors versus healthy tissues. To further investigate the reduction of
SCFA seemingly to be caused by ovarian tumors, butyric acid was also measure in the ceca where
it is produced. The effects of diet and disease on the levels of butyric acid in the ceca was consistent
with the effects observed in the ovaries- the birds fed a whole-flax diet had slightly higher levels
of butyric acid in the ceca compared to the control group, and there was a significant decrease in
butyric acid in birds with advanced stage ovarian cancer. This suggests that the cancer does not
necessarily decrease the fermentation of SCFA or the activity of the gut microbiota, but instead,
might increase the oxidation of SCFA in ovarian cancer cells because SCFA can readily diffuse
across the mitochondrial membrane, in contrast to longer chain fatty acids, to be implemented as
an energy source. If cancer cells are more quickly using up the stores of SCFA, this would
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contribute to why the significant decrease in butyric acid is observed in both the ceca and ovaries
collected from hens with ovarian cancer. Due to the significant increase in butyric acid levels
measured in the ovaries compared to the ceca, it is concluded that the SCFA do not remain in the
ceca for very long following fermentation, and are quickly transported to the liver to be stored
and/or transported to the target organ.
Overall, this study suggests that dietary flaxseed could upregulate the conversion of ALA
to DHA in ovarian cancer through an increase of OM3 PUFA over OM6. In addition, this increase
in OM3:OM6 PUFA ratio contributes to a decrease in AA, and as a result, a slight decrease in
PGE2. Through fermentation in the gut, the dietary fibers of flaxseed slightly increase the levels
of butyric acid in the ovaries. However, these levels are significantly reduced in ovarian cancer,
suggesting that SCFA are used as an energy source for ovarian cancer cells. These observations in
OM3 PUFA and SCFA in the ovaries produced as a result of a flaxseed supplemented diet could
provide insight into two possible mechanisms in which dietary flaxseed regulates metabolic
activity and gene expression to prevent or reduce the severity of ovarian cancer.
VII. Future Directions
Future studies include further exploration into the role of SCFA by measuring their
concentrations in the liver to acquire a better understanding of SCFA storage and movement within
the body and increasing the sample size of the experiments already performed in order to obtain
the most accurate results. Another future aim would include investigating the specific effects of
flaxseed on the desaturase and elongase enzyme activity.
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